Rhythm Pharma Q2 Revenue Jumps 19% to $71.3M; RM-718 Shows 11.6% BMI Reduction in Acquired HO
RYTM sits 41% above its 52-week low of $74.5.
Summary
Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M, up 19% sequentially, and announced positive preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity, showing an 11.6% mean BMI reduction.
Key Events · Earnings and Guidance · RYTM
-
Q2 Revenue Beats on Strong HO Launch
Net product revenue reached $71.3M, a 19% sequential increase, with U.S. revenue of $51.0M (up 38% QoQ) driven by the IMCIVREE launch for acquired hypothalamic obesity. Over 400 patient start forms were received from ~300 prescribers since FDA approval.
-
RM-718 Phase 2 Data Shows 11.6% BMI Reduction
Preliminary data from the ongoing Phase 2 trial of weekly injectable RM-718 in acquired HO patients demonstrated a mean BMI reduction of 11.6% at 16 weeks (n=7), comparable to setmelanotide and bivamelagon, with limited hyperpigmentation.
-
Cash Runway Extended to 24 Months
Cash, cash equivalents, and short-term investments totaled $330.9M as of June 30, 2026, expected to fund operations for at least 24 months, supporting pipeline advancement and global launches.
-
2026 Expense Guidance Reaffirmed
Non-GAAP operating expenses are projected at $363M–$397M for 2026, including R&D of $175M–$195M and SG&A of $188M–$202M, reflecting continued investment in commercial and clinical activities.
Analysis · RYTM · Life Sciences
A strong second quarter saw Rhythm Pharmaceuticals deliver $71.3 million in net product revenue, a 19% sequential gain fueled by the U.S. launch of IMCIVREE for acquired hypothalamic obesity. Early demand is robust, with more than 400 patient start forms coming from roughly 300 prescribers. The company also unveiled preliminary Phase 2 data for its next-generation weekly MC4R agonist RM-718, which achieved a clinically meaningful 11.6% mean BMI reduction at 16 weeks in acquired HO patients—results that stack up well against setmelanotide and bivamelagon. With $330.9 million in cash and a 24-month runway, Rhythm is well-funded to advance its pipeline and expand globally, including anticipated launches in Japan and Europe. The combination of accelerating commercial traction and positive pipeline data strengthens the investment thesis, though operating expenses remain elevated.
At the time of this filing, RYTM was trading at $105.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $74.50 to $122.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.